Evidence map›Paper›PMID 35501788›Full record

ArticleBMC endocrine disorders2022

Use of thyroid hormones in hypothyroid and euthyroid patients: a 2020 THESIS questionnaire survey of members of the Czech Society of Endocrinology.

Jan Jiskra, Jan Paleček, Roberto Attanasio, Laszlo Hegedüs, Endre V Nagy, Enrico Papini, Petros Perros, Roberto Negro, Michal Kršek

Open access · goldAbstract read
In one paragraph

Article in BMC endocrine disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Medically not yet explained symptoms in hypothyroidism.Nature reviews. Endocrinology · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?International journal of endocrinology and metabolism · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

Jan Jiskra3rd Department of Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic. jan.jiskra@vfn.cz.
Jan Paleček3rd Department of Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
Roberto AttanasioScientific Committee of Associazione Medici Endocrinologi, Milan, Italy.
Laszlo HegedüsDepartment of Endocrinology, Odense University Hospital, Odense, Denmark.
Endre V NagyDivision of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Enrico PapiniDepartment of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.
Petros PerrosDepartment of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
Roberto NegroDivision of Endocrinology, "V. Fazzi" Hospital, Lecce, Italy.
Michal Kršek3rd Department of Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
Charles University · CZAssociazione Medici Diabetologi · ITOdense University Hospital · DKOspedale Regina Apostolorum · ITOspedale Vito Fazzi · ITRoyal Victoria Infirmary · GBUniversity of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInconsistencies in the management of hypothyroidism have been reported among endocrinologists in different European countries. Aim of this study was to explore Czech endocrinologists' use of thyroid hormones in hypothyroid and euthyroid patients.

methodsWe used a web-based survey containing 32 questions regarding the use of thyroid hormones. Four-hundred thirty-two members of the Czech Society of Endocrinology received an e-mail invitation to participate in the survey.

resultsWe received and analysed 157 responses (112 females and 45 males) from the 432 members (36.3%). According to 99.4% of the respondents, levothyroxine (LT4) is the primary drug of choice for the treatment of hypothyroidism. Liothyronine (LT3) was used in clinical practice by 29.9% of responders. According to 90.5% of respondents, thyroid hormones may be indicated in biochemically euthyroid patients. Female physicians prescribe thyroid hormones in euthyroid infertile women with high antibody levels more frequently than male physicians (P = 0.003). Most Czech endocrinologists (76.4%) consider combined therapy with LT4 and LT3 in various clinical scenarios, but only 1 of 29 hypothyroid physicians (3.5%) would recommend it to their patients, and only 4 out of 128 respondents (3.1%) would consider LT3 or desiccated thyroid for themselves, if diagnosed with hypothyroidism.

conclusionLT4 is the primary thyroid hormone used in the Czech Republic for treatment of hypothyroidism. At variance with thyroid guideline recommendations, Czech endocrinologists are quite liberal when prescribing thyroid hormones to euthyroid patients and in the use of LT4/LT3 combination treatment for hypothyroid patients with persisting symptoms.

Indexed as

HypothyroidismInfertility, FemaleCzech RepublicFemaleHumansMaleSurveys and QuestionnairesThyroxineThyroxineEuthyroidismHypothyroidismLevothyroxineLiothyronineSurvey

Identifiers

PMID35501788
PMCPMC9063132
OpenAlexW4225305797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.